



Principles and Applications of Amniocentesis and Chorionic Villus Sampling (CVS) for Prenatal Diagnosis of Genetic Disorders

Rachmat Hidayat^{1*}

¹Department of Medical Biology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia

ARTICLE INFO

Keywords:

Chorionic villus sampling
Chromosome
Genetic study
Prenatal screening

***Corresponding author:**

Rachmat Hidayat

E-mail address:

rachmathidayat@fk.unsri.ac.id

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.59345/sjog.v1i2.95>

A B S T R A C T

The principles and implementation of amniocentesis and chorionic villus sampling (CVS) in the prenatal identification of genetic diseases play a crucial role in the healthcare of both the mother and the fetus. Both of these techniques share fundamental concepts, including the collection of the fetus's genetic material for genetic analysis. This process enables the identification of chromosomal anomalies such as trisomy and monosomy, as well as specific genetic illnesses caused by mutations in particular genes. Chromosome problems, such as Down syndrome and genetic diseases, such as cystic fibrosis, thalassemia, and muscular dystrophy, can be found with amniocentesis and CVS. The data derived from the outcomes of this genetic study is of immense value in aiding patients and physicians in making determinations regarding the continuation of the pregnancy, readiness for therapy, and subsequent postnatal care that may be necessary.

1. Introduction

Within the realm of maternal and prenatal healthcare, the identification of genetic disorders in the developing fetus holds significant importance. Amniocentesis and chorionic villus sampling (CVS) are diagnostic methods employed to obtain a sample of the fetus's genetic material for subsequent analysis. The fundamental premise underlying these two procedures is to detect any chromosomal or genetic abnormalities in the fetus. This information is crucial for the expecting couple to make informed decisions based on the analysis results. This article will explore the fundamental principles and practical uses of amniocentesis and CVS in the prenatal detection of genetic diseases. Additionally, it will highlight the

significant contribution of genetic counseling to assisting patients in navigating through this procedure. The identification of genetic diseases during pregnancy is crucial for ensuring proper medical attention and the provision of the required assistance to ensure the successful progression of a healthy pregnancy. When there are major genetic abnormalities, the data gathered by amniocentesis or CVS might impact choices regarding whether to continue the pregnancy, make plans for childbirth, and prepare the couple for any medical or child care needs that may arise after the baby is born.¹⁻⁶

Principles behind the procedures of amniocentesis and CVS

Amniocentesis and CVS are two procedures that share fundamental concepts, specifically the extraction of the fetus' genetic material for genetic analysis. While the fundamental idea remains unchanged, there are variations in the sampling technique and the timing of its implementation. These two processes, namely prenatal diagnosis and chromosomal analysis, are crucial techniques used to detect and diagnose any chromosomal or genetic abnormalities present in the developing fetus.⁷⁻¹⁰

Amniocentesis procedures

- **Sampling:** The process involves obtaining a sample of the amniotic fluid by putting a needle into the mother's uterus through the abdomen.
- **Optimal timing:** typically conducted throughout the gestational period, ranging from the 15th-20th week.
- **Genetic material source:** fetal cells found in amniotic fluid.

CVS procedure

- **Sampling:** The doctor obtains a specimen of the chorion tissue, which will later form the placenta, by inserting a needle either through the mother's vagina or abdomen.
- **Implementation timeframe:** It is possible to do the procedure at an earlier stage of pregnancy, specifically between the 10th and 13th weeks. Researchers derive the genetic material from a chorionic tissue sample that contains the genetic material of the fetus.

Analysis of the benefits and drawbacks of amniocentesis and CVS

Amniocentesis and CVS (Chorionic Villus Sampling) are two prenatal diagnostic techniques employed to detect chromosomal and genetic abnormalities in the developing child. It is important to carefully evaluate both options, considering the specific circumstances and medical guidelines, as they each have their own pros and cons.¹⁰⁻¹⁵ Below is a comprehensive analysis of the benefits and drawbacks of these two methods;

Amniocentesis

Benefits of amniocentesis

- **Enhanced safety:** Amniocentesis is often considered safer than CVS, with a lower risk of miscarriage. Amniocentesis often reduces the likelihood of experiencing a miscarriage.
- **Expanded knowledge:** Amniocentesis can yield more comprehensive data regarding the well-being of the fetus. Amniotic fluid can serve as a means to assess fetal lung maturity and detect infection, in addition to its application in genetic analysis.
- **Further testing:** Micromatrix analysis, a method capable of identifying minute chromosomal alterations, frequently employs amniocentesis.

Drawbacks of amniocentesis

- **Conducted during the second trimester:** Typically, doctors conduct amniocentesis during the second trimester of pregnancy, which causes a delay of several weeks before the results become available.
- **Complication risk:** Although the risk of miscarriage is lower compared to CVS, there is still a possibility of experiencing problems such as fetal injury or infection.

Chorionic villus sampling (CVS)

Benefits of CVS

- **Timely identification:** CVS can be conducted at an earlier stage of pregnancy, resulting in the expedited availability of genetic analysis outcomes. This enables patients to make decisions at an earlier stage of pregnancy.
- **Easier sampling:** The process of collecting chorionic tissue for chorionic villus sampling (CVS) is regarded as less complex compared to obtaining amniotic fluid for amniocentesis.

Drawbacks of CVS

- **Increased miscarriage risk:** CVS is associated with a greater likelihood of miscarriage compared to amniocentesis, particularly when conducted prior to the 10th week of pregnancy.
- **Restricted data:** CVS often offers information regarding chromosomal abnormalities rather than specific genetic illnesses. Consequently, it is important to note that CVS is not capable of detecting all categories of genetic abnormalities.

- In contrast to amniocentesis, CVS is not suitable for evaluating fetal lung maturity or infections.

Applications of amniocentesis and CVS

These two methods have several applications in the prenatal diagnosis of genetic diseases;¹⁶⁻²⁰

Detection of trisomy and monosomy

Amniocentesis and CVS are diagnostic procedures that can identify chromosomal abnormalities, including trisomy (e.g., Down syndrome) and monosomy (e.g., Turner syndrome). This data assists patients and physicians in making informed decisions on the continuation of the pregnancy and the subsequent postnatal care that may be required. Down syndrome is a prevalent chromosomal condition. Individuals with Down syndrome possess a trisomy of chromosome 21, meaning they have three copies of this chromosome instead of the usual two.

Amniocentesis and CVS are diagnostic procedures that can identify the presence of trisomy 21 in the fetus. This information is valuable for patients and clinicians, as it aids in making informed decisions regarding the continuation of the pregnancy and preparing for postnatal care. Trisomy 18 is an uncommon yet grave disorder. In this instance, the person possesses three duplicates of chromosome 18.

Amniocentesis and CVS are also viable methods for detecting Edwards syndrome. Trisomy 13 is a severe chromosomal abnormality characterized by the presence of an additional copy of chromosome 13. Amniocentesis and CVS methods can facilitate the identification of trisomy 13 in the fetus. Turner syndrome is an instance of monosomy, characterized by the presence of a single X chromosome in females instead of the usual two. Diagnostic procedures such as amniocentesis and CVS can identify the presence of monosomy X in the developing fetus.

Genetic abnormality identification

Aside from chromosomal abnormalities, these two techniques are also employed to identify particular genetic problems, such as gene mutations linked to specific hereditary ailments like cystic fibrosis. Cystic fibrosis is an inherited disorder that impacts the

respiratory and digestive systems. Amniocentesis and CVS procedures can identify genetic alterations linked to cystic fibrosis in the developing fetus.

Early detection of the condition can facilitate prompt diagnosis, enhancing subsequent treatment and postnatal management. Thalassemia is a collection of blood illnesses resulting from genetic abnormalities that impact the generation of hemoglobin. Amniocentesis and CVS are diagnostic procedures that can identify genetic alterations linked to thalassemia in the developing fetus.

This information facilitates patients and clinicians in strategizing the requisite care and administration postpartum. Muscular dystrophy refers to a collection of hereditary disorders that impact the musculature. Healthcare providers can employ prenatal techniques such as amniocentesis and CVS to identify genetic alterations linked to muscular dystrophy in the unborn child. This offers a chance to strategize suitable care and assistance.¹⁶⁻²⁰

2. Conclusion

The concepts and use of amniocentesis and CVS for finding genetic problems before birth are very important for both mom and baby's health. Both of these techniques share fundamental concepts, including the collection of the fetus's genetic material for genetic analysis. This process enables the identification of chromosomal anomalies such as trisomy and monosomy, as well as specific genetic illnesses caused by mutations in particular genes.

3. References

1. American College of Obstetricians and Gynecologists. Practice bulletin No. 163: screening for fetal aneuploidy. *Obs Gyn.* 2019;33(3):e215-29.
2. Pandya PP, Snijders RJM. Amniocentesis and chorionic villus sampling in multiple pregnancy. *Multiple Pregnancy.* Springer. 1995: pp.153-64.
3. Wald NJ, Kennard A, Hackshaw A. Antenatal chorionic villus sampling and amniocentesis: Risk of fetal loss. *Lancet.* 1992;340(8810):1232-3.

4. Alfirevic Z, Sundberg K. Amniocentesis and chorionic villus sampling for prenatal diagnosis. *Cochrane Database Syst Rev.* 2003;3:CD003252.
5. Simpson JL. Chorionic villus sampling and amniocentesis. A practice of anesthesia for infants and children Elsevier. 2010: pp. 673-6.
6. Valente MM. Chorionic villus sampling (CVS) versus amniocentesis for pre-natal diagnosis: A prospective study in 1003 cases. *Ultrasound Obs Gyn.* 1998;11(6):402-11.
7. Hobbins JC, Grannum P, Berkowitz RL, Mahoney MJ. Chorionic villus sampling as an alternative to amniocentesis in high-risk patients. *Obs Gyn.* 1984;64(5):615-8.
8. Nicolaides KH, Fisk NM. Combined amniocentesis and chorionic villus sampling in early pregnancy. *Lancet.* 1988;331(8587):1075-7.
9. Firth HV, Hurst JA. Aneuploidy. Smith's recognizable patterns of human deformation. Elsevier. 2001:pp. 132-8.
10. Bahado-Singh RO, Poon LC. Antenatal testing for aneuploidy and neural tube defects. In *Obstetrics in Family Medicine* Springer. 2014: pp. 441-51.
11. Gates EA, Stabile I, Reece MT. Early midtrimester chorionic villus sampling versus amniocentesis: A prospective randomized study. *Am J Obs Gyn.* 1985;153(6):619-22.
12. Bianchi DW, Crombleholme TM, D'Alton ME. Clinical experience with transabdominal chorionic villus sampling and early midtrimester amniocentesis. *Obs Gyn.* 2000;95(5): 625-9.
13. Alfirevic Z, Mi J, Ghi T. Amniocentesis and chorionic villus sampling for prenatal diagnosis. *Cochrane Database Sys Rev.* 2017;9:CD003252.
14. Williams J, Fliegner M. Antenatal diagnosis of genetic disease: chorionic villus sampling vs. amniocentesis. *Austr New Zealand J Obs Gyn.* 1999;39(4):457-61.
15. Brambati B, Simoni G, Danesino C. Chorionic villus sampling. In *Fetal Medicine* Springer. 1994: pp. 345-73.
16. Khalek N, Johnson MP, Moldenhauer JS. Ethical issues surrounding prenatal diagnosis and fetal therapy. In *Clinical Ethics in Pediatrics.* Springer. 2013: pp. 97-115.